|
|||||
|
|
| CYP2C19基因检测在氯吡格雷治疗中的临床意义 | |
| 引用本文： | 宋莹,袁晋青. CYP2C19基因检测在氯吡格雷治疗中的临床意义[J]. 中国分子心脏病学杂志, 2014, 0(4): 1039-1042 |
| 作者姓名： | 宋莹 袁晋青 |
| 作者单位： | 中国医学科学院北京协和医院国家心血管病中心阜外心血管病医院心内科,北京市100037 |
| 基金项目： | 国家“十二五”科技支撑计划（2011BA111B07） |
| 摘 要： | 氯吡格雷对血小板抑制作用具有个体化差异。接受标准化氯吡格雷治疗的患者仍然发生了不良心血管事件。CYP2C19基因多态性是较为公认的内在遗传因素。大量研究证实CYP2C19功能缺失基因与心血管事件风险增加相关,尤其是支架内血栓事件。替格瑞洛和替卡格雷是可能的替换药物。本文围绕CYP2C19基因多态性及临床应用做一综述。 |
| 关 键 词： | CYP2C19 基因多态性 替格瑞洛 普拉格雷 |
Clinic Application of CYP2C19 Gene Test in Clopidogrel Therapy |
|
| Affiliation: | SONG Ying, YUAN Jin-qin.(Department of Cardiology, Fuwai Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, 10037, China) |
| Abstract: | Clopidogrel-induced platelet inhibition is patient-specifc. Despite providing a standard dose of clopidogrel to patients, adverse cardiovasucular events still occurrs. Genetic polymorphisms of the CYP2C19 are considered to be the most important internal factor. Lots of clinic materials demonstrate the relationship of CYP2C19 loss of funtion mutation and increased adverse cardiovascular events especially stent thrombosis following percutanous coronary intervention（PCI）. Ticagrelor and prasugrel are probably substitutions of clopidogrel. This article discusses genetic polymorphisms of the CYP2C19 and its clinical application. |
| Keywords: | CYP2C19 Polymorphisms Ticagrelor Prasugrel |
| 本文献已被 维普 等数据库收录！ | |